{"created":"2023-06-20T15:59:57.792423+00:00","id":18135,"links":{},"metadata":{"_buckets":{"deposit":"d5c77852-1b7c-440b-bb1b-93ef9b4b7dfa"},"_deposit":{"created_by":28,"id":"18135","owners":[28],"pid":{"revision_id":0,"type":"depid","value":"18135"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00018135","sets":["172:173:675"]},"author_link":["27710","68849","67314","67317","68848","33750","27713","33751","67316","67315","33748","68847"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-03-31","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"32","bibliographicPageStart":"25","bibliographicVolumeNumber":"39","bibliographic_titles":[{"bibliographic_title":"日本赤十字社和歌山医療センター医学雑誌"},{"bibliographic_title":"Medical Journal of Japanese Red Cross Wakayama Medical Center","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【背景】\n免疫チェックポイント阻害剤(ICI)は,画期的な癌治療薬であるが,免疫関連有害事象として1型糖尿病(ICI-T1DM)が発症することがある.ICI-T1DMは重症疾患であるが,そのリスク因子は不明である.\n【方法】\nICI-T1DMのリスク因子を明らかにするため,我々はその臨床経過を評価し,HLA-DRアリルおよびそのアミノ酸配列を検討した.\n【結果】\n8名がICI-T1DMと診断された.発症時に随時血糖が400 mg/dl以上に急激に悪化していた.7名が,ケトーシスあるいはケトアシドーシスを呈した.随時血中Cペプチド値は,全ての患者において1か月以内に測定感度以下となった.ICI-T1DM患者はコントロール患者と比較して,HLA-DRβ1鎖86位のアミノ酸（β86）がG：グリシンの頻度がV：バリンの頻度よりも有意に増加していた（P＝0.042,オッズ比 5.13）.\n【考察】\nICI-T1DMはT1DMとF1DMの混合あるいは中間の発症様式を有し,β86GがICI-T1DMの新規リスク因子であることが明らかとなった.","subitem_description_type":"Abstract"}]},"item_10001_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{}],"names":[{"name":"INABA, Hidefumi"}]},{"nameIdentifiers":[{}],"names":[{"name":"KAIDO, Yosuke"}]},{"nameIdentifiers":[{}],"names":[{"name":"Ito, Saya"}]},{"nameIdentifiers":[{}],"names":[{"name":"HIROHATA, Tomonao"}]},{"nameIdentifiers":[{}],"names":[{"name":"MORIMOTO, Naomi"}]},{"nameIdentifiers":[{}],"names":[{"name":"Inoue, Gen"}]}]},"item_10001_heading_23":{"attribute_name":"見出し","attribute_value_mlt":[{"subitem_heading_banner_headline":"原著論文","subitem_heading_language":"ja"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本赤十字社和歌山医療センター"}]},"item_10001_relation_16":{"attribute_name":"情報源","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"日本赤十字社和歌山医療センター"}]}]},"item_10001_rights_15":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"日本赤十字社和歌山医療センター"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1341-9927","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"稲葉, 秀文"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"海道, 陽介"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"伊藤, 沙耶"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"廣畠, 知直"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"森本, 奈緒美"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"井上, 元"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-05-16"}],"displaytype":"detail","filename":"vol.39 稲葉秀文.pdf","filesize":[{"value":"545.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Vol.39-05","url":"https://redcross.repo.nii.ac.jp/record/18135/files/vol.39 稲葉秀文.pdf"},"version_id":"0666898c-264c-4fc1-96d3-8142810a79f6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"免疫チェックポイント","subitem_subject_scheme":"Other"},{"subitem_subject":"Ⅰ型糖尿病","subitem_subject_scheme":"Other"},{"subitem_subject":"ヒト主要組織適合性遺伝子複合性（HLA）","subitem_subject_scheme":"Other"},{"subitem_subject":"Immune-checkpoint inhibitors","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immune-related adverse events","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"type 1 diabetes mellitus","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Human histocompatibility leukocyte antigen","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"免疫チェックポイント阻害剤による1型糖尿病の臨床的特徴およびリスク因子","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"免疫チェックポイント阻害剤による1型糖尿病の臨床的特徴およびリスク因子"},{"subitem_title":"Clinical characteristics and risk factors of Type 1 diabetes mellitus induced by  immune‐checkpoint inhibitors","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"28","path":["675"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-05-16"},"publish_date":"2022-05-16","publish_status":"0","recid":"18135","relation_version_is_last":true,"title":["免疫チェックポイント阻害剤による1型糖尿病の臨床的特徴およびリスク因子"],"weko_creator_id":"28","weko_shared_id":-1},"updated":"2023-06-20T17:46:32.696691+00:00"}